Biopharma has suffered some scares this year in Washington, D.C., and on Wall Street, but from a science perspective, the industry has performed admirably, particularly with big advances in cancer immunotherapy and gene therapy.

I pored over spreadsheets, dug deep into medical journals, stared at stock charts, and consulted my beloved dog, Bo, to determine this year’s nominees for best biopharma CEO. There were some hard decisions to make and a few worthy candidates didn’t make the cut, mainly because the bar this year was so high. Congratulations to each of the finalists.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy